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on HIV-positive patient using highly active
antiretroviral therapy: Case report and
a review of the literatureKishore Shetty *LSU Health Sciences Center, Oral and Maxillofacial Surgery, 1100 Florida Avenue,
#127, New Orleans, LA 70119, United StatesReceived 9 June 2005; accepted 10 June 2005Summary This article reports an unusual presentation of an oral KS lesion in an
HIV-positive HAART-naı¨ve patient three years after diagnosis. The lesions gradually
decreased in size subsequent to the initiation of HAART. KS lesions may regress after
HAART begins, suggesting that the recovery of the immune system and a direct anti-
viral effect against human herpes virus 8 (HHV-8) may largely cause this improve-
ment.c 2005 Elsevier Ltd. All rights reserved.
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dIntroduction
Oral manifestations of human immunodeficiency
virus (HIV) infection have been recognized since
the onset of the HIV pandemic and are important
indicators of the natural history of the disease as
shown by their inclusion in the Walter reed staging
classification and the listing of indicator symptoms
of the Centers for Disease Control & Prevention.
Kaposi’s sarcoma (KS) is the malignancy most often
associated with HIV infection because of its pro-741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reser
oi:10.1016/j.ooe.2005.06.006
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E-mail address: kshett@lsuhsc.edupensity to develop in HIV-positive individuals. Pa-
tients with lesions of the oral mucosa may have a
higher death rate than those with exclusively
cutaneous manifestations of KS. After diagnosis,
patients with cutaneous KS survive longer than
patients with oral lesions.
After the advent of highly active antiretroviral
therapy (HAART), the pattern of oral manifesta-
tions in people living with HIV disease has changed
and may continue to shift as a result of the avail-
ability of medicine and adherence to medications.
New cases of KS usually occur in HAART-naı¨ve pa-
tients with advanced immunosupression, and these
cases reflect delayed diagnosis and treatment of
HIV infection.ved.
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an oral KS lesion in an HIV-positive HAART-naı¨ve
patient. The patient, who was diagnosed with HIV
more than three years ago, refused HAART medica-
tions due to religious reasons. Three years later he
developed oral KS lesions.Figure 1 A generalized, diffuse, reddish-blue, soft,
macular enlargement bilaterally on the posterior right
hard palate was observed, with ill-defined margins
extending to and involving the soft palate.
Figure 2 A medium power photomicrograph of a non-
encapsulated spindle cell proliferation (H&E Stain 40·).Case report
A 32-year-old African–American male patient was
referred by his physician to the Oral Surgery Clinic
at the Louisiana State University Medical Center for
evaluation of palatal enlargement and discolor-
ation. He first noticed ‘‘a discoloration on the roof
of his mouth’’ four months before presenting to his
physician. It had been steadily increasing in
size since its appearance. He failed to seek medi-
cal attention for this lesion since it was not painful
and did not bleed. He also reported unexplained
weight loss in the last six months (approxi-
mately 20 pounds) and febrile episodes. On hospi-
tal admission his CD4+ lymphocyte count was
127 cells/cc3 and his viral load was 18,000. He
reported no known drug allergy. He denied
tobacco use, illicit drug use, or intravenous drug
use. He reported a history of drinking two pints
of whiskey a week for 12 years but stopped four
months ago.
His previous medical history was significant for
HIV diagnosed three years prior to his visit to the
Internal Medicine Clinic. At that time, he had re-
fused any antiretroviral medications due to reli-
gious reasons. At the time of diagnosis his CD4+
lymphocyte count was 367 cells/cc3 with no
detectable viral load. He had been monitored by
a specialist in infectious disease since his diagnosis
but then was lost to medical follow-up. The patient
said he had sought herbal medicine therapy for a
while and thought he was cured.
The extraoral examination found that he was
normocephalic with facial symmetry and had no
sign of body mass wasting. Non-tender palpable
neck lymphadenopathy was appreciated on his left
submandibular and posterior cervical chains; the
nodes were firm, mobile, and painless. No signs
or symptoms of acute infection, swelling, or ten-
derness were observed extraorally.
The intraoral examination found poor oral hy-
giene with moderate dental plaque and calculus
accumulation. Bleeding on periodontal probing
was generalized. There was no radiographic evi-
dence of bone loss, and the deepest probing was
4 mm. A generalized, diffuse, reddish-blue, soft,
macular enlargement bilaterally on the posteriorright hard palate was observed, with ill-defined
margins extending to and involving the soft palate
(Fig. 1). There was no tenderness. The patient de-
nied any history of dysphagia or dyspnea or diffi-
culty chewing associated with this lesion. There
were no other oral lesions, tumors, or masses
noted. The patient agreed to undergo an incisional
biopsy of the lesion on the palate. A local anesthe-
sia infiltration was obtained using 1.8 mL of lido-
caine 2% with epinephrine 1:100,000. The lesion
was placed in 10% formalin and submitted for histo-
pathological diagnosis.
The histologic examination revealed a cellular
spindle tumor within the connective tissue, numer-
ous extravasated erythrocytes, and poorly defined
vascular slits (Figs. 2 and 3). These microscopic
findings plus the clinical presentation and the
Figure 3 A high power photomicrograph of a spindle
cell proliferation exhibiting plump nuclei with focal
hyperchromatism, capillary and slit-like vascular spaces,
and red blood cell extravasation suggestive of a diagnosis
of Kaposi’s sarcoma (H&E Stain 100·).
228 K. Shettymedical history were consistent with a diagnosis of
AIDS-related Kaposi’s sarcoma. Additionally, head-
and-neck magnetic resonance imaging (MRI) with
contrast solution was ordered for further assess-
ment of respiratory and/or esophageal tract
obstruction. No major obstruction of upper airways
was observed in the MRI, but multiple scalp lesions
consistent with KS were noted.
The patient subsequently agreed to start HAART
therapy and was placed on nevirapine (Viramune;
Boehringer Ingelheim Corporation, CT, USA), riton-
avir (Kaletra; Abbott Laboratories, IL, USA) and
abacavir (Ziagen; Glaxosmithkline, Munich, Ger-
many). The oral KS lesions have decreased in size
since the initiation of HAART (Fig. 4).Figure 4 The lesions have decreased in size 3 months
after the initiation of highly active antiretroviral
therapy.Discussion
First described by the Hungarian dermatologist
Moritz Kaposi in 1872, KS is a multifocal neoplasm
of vascular endothelial cell origin. Before the mid
1980s, KS was rare and found classically on elderly
men of Italian, Jewish, or Slavic ancestry. With the
advent of the AIDS epidemic, KS has become one of
the most common malignancies associated with HIV
infection and was one of the first diseases to define
AIDS in 1981.
KS is traditionally separated into four different
types: classic, which primarily affects elderly
men of Mediterranean and eastern European origin;
endemic, which is common in parts of Africa; epi-
demic or AIDS-associated; and transplantation-
associated.1 The human herpes virus-8 infection
and its pathogenic process characterize all four
types. Although most Americans remain at low risk
for infection of AIDS-HHV-8 KS, homosexual and
bisexual men are at strikingly high risk as a result
of sexual transmission in some form.2
KS sometimes begins as a single lesion of the oral
mucosa but more frequently begins as multiple le-
sions. Fifty percent of the affected patients show
oral lesions and 20–25% of these lesions may be
the initial site of involvement.3 KS can invade bone
and create tooth mobility when involves it the pal-
ate or gingiva. The lesion initially is a flat brown or
reddish purple macule that does not blanch with
pressure. The neoplasm may develop into plaques
or nodules, and this progressive malignancy may
disseminate to lymph nodes and organ systems.
Morbidity of KS oral lesions may be associated
with pain, bleeding, and functional interferences
caused by the tumor.
KS afflicts 10–20% of HIV-positive patients.4
Some studies suggest that HIV-positive patients
with Kaposi’s sarcoma have a shorter survival than
might be predicted from their CD4 concentrations,5
but other studies do not find such a correlation.6
One study proposed KS as a prognostic marker for
patients who do not receive HAART.7 The authors
reported that patients with lesions of the oral
mucosa had a higher death rate than those with
exclusively cutaneous manifestations of the dis-
ease. After diagnosis, patients with cutaneous
KS survived longer than patients with oral KS (med-
ian 72 months [26–118] vs. 24 months [19–29];
p = 0.001). Another interesting finding of this study
was that patients with oral KS and a CD4 cell count
of at least 150/lL had a similar mortality risk as pa-
tients with the cutaneous disease but CD4 cell con-
centration of no more than 150/lL.
A significant decrease in the incidence of KS has
coincided with an increased use of potent antiret-
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One study indicates that KS lesions may regress
after initiating HAART that includes at least one
PI, suggesting that this improvement may be lar-
gely caused by the recovery of the immune system
and a direct antiviral effect against KS.9 A recent
study has also reported a decreased incidence of
KS with non-nucleotide reverse transcriptase inhib-
itor (NNRTI)-based therapy;10 the authors also
reported that PI- and NNRTI-based HAART regi-
mens are as equally protective against KS. Some
data now suggest that new cases of KS usually
occur in antiretroviral-naı¨ve patients with
advanced immunosupression, and these new cases
reflect delayed diagnosis and treatment of HIV-1
infection.11
The pace of AIDS-related KS is quite variable,
ranging from a very indolent process requiring lit-
tle, if any, therapy, to a rapidly progressive disease
leading to patient demise. Multiple therapeutic op-
tions exist, and each must be evaluated in terms of
the specific needs of the patient. HAART targets
the underlying HIV infection, thereby improving
immune function and, as far as we know, leading
to improvements in existing KS. Various local ther-
apies aim to eradicate small lesions; however, they
do not affect the KS in general nor the likelihood
of its recurrence. Systemic chemotherapy treats
extensive visceral involvement, which no other
form of treatment may affect. Newer treatment
approaches are aimed at HHV-8 or at the inflamma-
tory cytokine or angiogenic milieu necessary for KS
growth. KS treatment has been rapidly improving
with many new options currently under study or
recently proven to be efficacious and licensed for
use in patients with AIDS.
This article, reports an unusual presentation of
an oral KS lesion in an HIV-positive HAART-naı¨ve
patient three years after diagnosis. The lesions
gradually decreased in size subsequent to the initi-
ation of HAART. KS lesions may regress after HAARTbegins, suggesting that the recovery of the immune
system and a direct antiviral effect against human
herpes virus 8 (HHV-8) may largely cause this
improvement.References
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